Search
Hydrocortisone phosphate
go.drugbank.com/drugs/DB14542ApprovedInvestigationalVet approvedCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InducersIvosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigationalIvosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, b...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesPrednisolone hemisuccinate
go.drugbank.com/drugs/DB14633InvestigationalCategories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersEnsartinib
go.drugbank.com/drugs/DB14860ApprovedInvestigationalNon-small cell lung cancer (NSCLC) is one of the most frequent subtypes of lung cancers and encompasses a variety of different lung cancers, with notable ones being adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Ensar...
Categories: P-glycoprotein substratesCefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigationalCefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other β-lactam antibiotics.[FDA Label] Unlike other agents in this category, cefiderocol is a siderophore able to undergo active transport into...
Mipicoledine
go.drugbank.com/drugs/DB15075InvestigationalMipicoledine is under investigation in clinical trial NCT01048008 (Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer).
Categories: P-glycoprotein substratesUpadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigationalUpadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmu...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsTepotinib
go.drugbank.com/drugs/DB15133ApprovedInvestigationalTepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 an...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesDeutivacaftor
go.drugbank.com/drugs/DB15141ApprovedInvestigationalDeutivacaftor is a small molecule cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. It is used alongside CFTR correctors to increase the quantity and function of CFTR at the cell surface in patients with cystic fibr...
Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsAvapritinib
go.drugbank.com/drugs/DB15233ApprovedInvestigationalAvapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mast...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates